Could KP405 offer a new way to tackle Parkinson's?

NCT ID NCT06189170

Completed Disease control Sponsor: Kariya Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This early-stage trial is evaluating the safety and tolerability of an experimental drug called KP405, which is being developed as a potential treatment for Parkinson's disease. The study will first give single and then multiple doses to healthy volunteers, and later include people with Parkinson's, to see how the drug is processed by the body and whether it causes any side effects. The goal is to gather essential safety data before larger studies can explore whether KP405 can actually help manage the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KP405
What this could lead to: If KP405 proves safe and well-tolerated, it could pave the way for a new treatment option to help manage Parkinson's disease symptoms.
What could go wrong: This is an early-phase trial focused on safety, not effectiveness. The drug may not work as hoped, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SAFETY ISSUES TOLERANCE

Contacts and locations

Locations

MAC

Manchester, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.